Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.

Johnson & Johnson has submitted a NDA seeking approval from the FDA for icotrokinra to treat moderate to severe plaque psoriasis (PsO).

Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North Carolina. The latest manufacturing investment will support the ongoing development of ...